Residential College | false |
Status | 已發表Published |
S-adenosyl-L-methionine (SAMe), cannabidiol (CBD), and kratom in psychiatric disorders: Clinical and mechanistic considerations | |
Taylor Levine, M.1; Gao, Jin2,3; Satyanarayanan, Senthil Kumaran4,5; Berman, Sarah1; Rogers, Jack T.2; Mischoulon, David1 | |
2020-03-01 | |
Source Publication | Brain, Behavior, and Immunity |
ISSN | 0889-1591 |
Volume | 85Pages:152-161 |
Abstract | Given the limitations of prescription antidepressants, many individuals have turned to natural remedies for the management of their mood disorders. We review three selected natural remedies that may be of potential use as treatments for depressive disorders and other psychiatric or neurological conditions. The best studied and best supported of these three remedies is S-adenosyl-L-methionine (SAMe), a methyl donor with a wide range of physiological functions in the human organism. With the increasing legalization of cannabis-related products, cannabidiol (CBD) has gained popularity for various potential indications and has even obtained approval in the United States and Canada for certain neurological conditions. Kratom, while potentially useful for certain individuals with psychiatric disorders, is perhaps the most controversial of the three remedies, in view of its greater potential for abuse and dependence. For each remedy, we will review indications, doses and delivery systems, potential anti-inflammatory and immunomodulatory action, adverse effects, and will provide recommendations for clinicians who may be considering prescribing these remedies in their practice. |
Keyword | Cannabidiol Cbd Kratom S-adenosyl-l-methionine Same |
DOI | 10.1016/j.bbi.2019.07.013 |
URL | View the original |
Indexed By | SCIE ; SSCI |
Language | 英語English |
WOS Research Area | Immunology ; Neurosciences & Neurology ; Psychiatry |
WOS Subject | Immunology' Neurosciences ; Psychiatry |
WOS ID | WOS:000527886000016 |
Scopus ID | 2-s2.0-85068958747 |
Fulltext Access | |
Citation statistics | |
Document Type | Journal article |
Collection | University of Macau |
Corresponding Author | Mischoulon, David |
Affiliation | 1.Depression Clinical and Research Program, Massachusetts General Hospital and Harvard Medical School, Boston, United States 2.Neurochemistry Laboratory, Department of Psychiatry, Massachusetts General Hospital and Harvard Medical School, Boston, United States 3.Department of Clinical Psychology, Qilu Hospital of Shandong University, Qingdao, China 4.Department of Psychiatry & Mind-Body Interface Laboratory (MBI-Lab), China Medical University Hospital, Taichung, Taiwan 5.State Key Laboratory of Quality Research in Chinese Medicine, Institute of Chinese Medical Sciences, University of Macau, Macao |
Recommended Citation GB/T 7714 | Taylor Levine, M.,Gao, Jin,Satyanarayanan, Senthil Kumaran,et al. S-adenosyl-L-methionine (SAMe), cannabidiol (CBD), and kratom in psychiatric disorders: Clinical and mechanistic considerations[J]. Brain, Behavior, and Immunity, 2020, 85, 152-161. |
APA | Taylor Levine, M.., Gao, Jin., Satyanarayanan, Senthil Kumaran., Berman, Sarah., Rogers, Jack T.., & Mischoulon, David (2020). S-adenosyl-L-methionine (SAMe), cannabidiol (CBD), and kratom in psychiatric disorders: Clinical and mechanistic considerations. Brain, Behavior, and Immunity, 85, 152-161. |
MLA | Taylor Levine, M.,et al."S-adenosyl-L-methionine (SAMe), cannabidiol (CBD), and kratom in psychiatric disorders: Clinical and mechanistic considerations".Brain, Behavior, and Immunity 85(2020):152-161. |
Files in This Item: | There are no files associated with this item. |
Items in the repository are protected by copyright, with all rights reserved, unless otherwise indicated.
Edit Comment